{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:51Z","timestamp":1789419831200,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01243-8","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:03:09Z","timestamp":1723096989000},"page":"2653-2668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-8377","authenticated-orcid":false,"given":"Mark G.","family":"Kirchhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5463","authenticated-orcid":false,"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9719-0810","authenticated-orcid":false,"given":"Catherine","family":"Maari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-9050","authenticated-orcid":false,"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"4","key":"1243_CR1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s13555-022-00706-0","volume":"12","author":"GM Peck","year":"2022","unstructured":"Peck GM, Roberson FA, Feldman SR. Why do patients in the United States seek care from dermatologists? Dermatol Ther. 2022;12(4):1065\u201372.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1243_CR2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1243_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","volume":"7","author":"M Megna","year":"2016","unstructured":"Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther. 2016;7(1):1\u201323.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1243_CR4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/cyto.2002.1043","volume":"18","author":"AE Hunt","year":"2002","unstructured":"Hunt AE, Williams LM, Lali FV, Foxwell BMJ. IL-4 regulation of p38 MAPK signalling is dependent on cell type. Cytokine. 2002;18(6):295\u2013303.","journal-title":"Cytokine"},{"issue":"1","key":"1243_CR5","first-page":"163","volume":"116","author":"PJ Lee","year":"2006","unstructured":"Lee PJ, Zhang X, Shan P, et al. ERK1\/2 mitogen-activated protein kinase selectively mediates IL-13\u2013induced lung inflammation and remodeling in vivo. J Clin Invest. 2006;116(1):163\u201373.","journal-title":"J Clin Invest"},{"issue":"suppl 2","key":"1243_CR6","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):ii111\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1243_CR7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521\u201346.","journal-title":"Drugs"},{"key":"1243_CR8","unstructured":"OPZELURA (ruxolitinib cream) prescribing information. [Internet]. 2023 [cited 2023 Jul 12]. https:\/\/www.opzelura.com\/prescribing-information.pdf."},{"key":"1243_CR9","unstructured":"OPZELURA (ruxolitinib cream). Summary of Product Characteristics. [Internet]. 2023 [cited 2023 Jul 12]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opzelura-epar-product-information_en.pdf."},{"key":"1243_CR10","unstructured":"Japan Tobacco. Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM(R) Ointment 0.25% in Japan [Internet]. 2021 [cited 2023 Jul 12]. https:\/\/www.torii.co.jp\/en\/release\/2021\/20210526_E1.pdf."},{"key":"1243_CR11","unstructured":"Lilly USA. OLUMIANT (baricitinib) prescribing information [Internet]. 2022 [cited 2023 Jan 6]. https:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf."},{"key":"1243_CR12","unstructured":"Eli Lilly. OLUMIANT (baricitinib) summary of product characteristics [Internet]. 2023 [cited 2023 Nov 6]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf."},{"key":"1243_CR13","unstructured":"Eli Lilly Canada Inc. OLUMIANT (baricitinib) product monograph [Internet]. 2022 [cited 2023 Jan 6]. https:\/\/pdf.hres.ca\/dpd_pm\/00066474.PDF."},{"key":"1243_CR14","unstructured":"Pfizer Inc. CIBINQO (abrocitinib) prescribing information. [Internet]. 2022 [cited 2023 Jan 6]. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=16652."},{"key":"1243_CR15","unstructured":"Pfizer Europe. CIBINQO (abrocitinib) summary of product characteristics [Internet]. 2021 [cited 2023 Jan 6]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf."},{"key":"1243_CR16","unstructured":"Pfizer Canada. CIBINQO (abrocitinib) product monograph [Internet]. 2022 [cited 2023 Jan 6]. https:\/\/www.pfizer.ca\/files\/CIBINQO_PM_EN.pdf."},{"key":"1243_CR17","unstructured":"AbbVie Inc. RINVOQ (upadacitinib) prescribing information. [Internet]. 2022 [cited 2023 Jan 6]. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf."},{"key":"1243_CR18","unstructured":"AbbVie GmBH. RINVOQ (upadacitinib) summary of product characteristics [Internet]. 2019 [cited 2023 Jan 6]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf."},{"key":"1243_CR19","unstructured":"AbbVie Corporation. RINVOQ (upadacitinib) product monograph [Internet]. 2022 [cited 2023 Jan 6]. https:\/\/pdf.hres.ca\/dpd_pm\/00068075.PDF."},{"issue":"1","key":"1243_CR20","first-page":"4","volume":"27","author":"MMK Shalabi","year":"2022","unstructured":"Shalabi MMK, Garcia B, Coleman K, Siller A, Miller AC, Tyring SK. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Ther Lett. 2022;27(1):4\u20139.","journal-title":"Skin Ther Lett"},{"issue":"1","key":"1243_CR21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002236","volume":"8","author":"TW Kragstrup","year":"2022","unstructured":"Kragstrup TW, Glintborg B, Svensson AL, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8(1): e002236.","journal-title":"RMD Open"},{"key":"1243_CR22","unstructured":"EMA. European Medicines Agency. 2022 [cited 2023 Jan 22]. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic."},{"key":"1243_CR23","unstructured":"Government of Canada. Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy\u2014Recalls, advisories and safety alerts\u2014Canada.ca [Internet]. Government of Canada, Health Canada, Marketed health products; 2022 [cited 2023 Jan 29]. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/janus-kinase-inhibitors-and-risk-major-adverse-cardiovascular-events-thrombosis."},{"issue":"4","key":"1243_CR24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"1243_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","volume":"82","author":"L Hoisnard","year":"2023","unstructured":"Hoisnard L, Vegas LP, Dray-Spira R, Weill A, Zureik M, Sbidian E. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2023;82(2):182\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1243_CR26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81(6):798\u2013804.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1243_CR27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/03007995.2022.2088715","volume":"38","author":"ME Montez-Rath","year":"2022","unstructured":"Montez-Rath ME, Lubwama R, Kapphahn K, et al. Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population. Curr Med Res Opin. 2022;38(8):1431\u20137.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1243_CR28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/ijd.15853","volume":"61","author":"H Wood","year":"2022","unstructured":"Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol. 2022;61(6):746\u201354.","journal-title":"Int J Dermatol"},{"key":"1243_CR29","volume":"8","author":"M Le","year":"2021","unstructured":"Le M, Berman-Rosa M, Ghazawi FM, et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front Med (Lausanne). 2021;8: 682547.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"1243_CR30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.36849\/JDD.7187","volume":"21","author":"S Daniele","year":"2022","unstructured":"Daniele S, Bunick C. JAK inhibitor safety compared to traditional systemic immunosuppressive therapies. J Drugs Dermatol. 2022;21(12):1298\u2013303.","journal-title":"J Drugs Dermatol"},{"key":"1243_CR31","unstructured":"Brunton L, Chabner BA, Knollman B. Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, 12th Edition.pdf [Internet]. [cited 2023 May 9]. https:\/\/www.docdroid.net\/JDeELxO\/goodman-gilmans-the-pharmacological-basis-of-therapeutics-12th-edition-pdf."},{"issue":"5","key":"1243_CR32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","volume":"16","author":"JJ Coleman","year":"2016","unstructured":"Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016;16(5):481\u20135.","journal-title":"Clin Med"},{"issue":"5","key":"1243_CR33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s13555-022-00722-0","volume":"12","author":"KA Papp","year":"2022","unstructured":"Papp KA, Beecker J, Cooper C, et al. Use of systemic therapies for treatment of psoriasis in people living with controlled HIV: inference-based guidance from a multidisciplinary expert panel. Dermatol Ther. 2022;12(5):1073\u201389.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1243_CR34","doi-asserted-by":"crossref","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat. 2023;34(1):2161812.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"1243_CR35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1243_CR36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1243_CR37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"32","key":"1243_CR38","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"3","key":"1243_CR39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","volume":"22","author":"B King","year":"2021","unstructured":"King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395\u2013405.","journal-title":"Am J Clin Dermatol"},{"issue":"10215","key":"1243_CR40","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","volume":"394","author":"FJ Brunner","year":"2019","unstructured":"Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394(10215):2173\u201383.","journal-title":"Lancet"},{"issue":"10","key":"1243_CR41","first-page":"857","volume":"61","author":"GM Allan","year":"2015","unstructured":"Allan GM, Lindblad AJ, Hudson B, et al. Simplified lipid guidelines: prevention and management of cardiovascular disease in primary care. Can Fam Physician. 2015;61(10):857\u201367.","journal-title":"Can Fam Physician"},{"issue":"9602","key":"1243_CR42","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829\u201339.","journal-title":"Lancet"},{"issue":"13","key":"1243_CR43","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","volume":"76","author":"MJ Domanski","year":"2020","unstructured":"Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1243_CR44","first-page":"694","volume":"37","author":"EHS Choy","year":"2019","unstructured":"Choy EHS, Miceli-Richard C, Gonz\u00e1lez-Gay MA, et al. The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694\u2013704.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"1243_CR45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","volume":"77","author":"PC Taylor","year":"2018","unstructured":"Taylor PC, Kremer JM, Emery P, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018;77(7):988\u201395.","journal-title":"Ann Rheum Dis"},{"key":"1243_CR46","unstructured":"European Medicines Agency. Assessment report: Cibinqo [Internet]. 2021 [cited 2023 May 25]. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/cibinqo-epar-public-assessment-report_en.pdf."},{"issue":"3","key":"1243_CR47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","volume":"18","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol. 2022;18(3):295\u2013307.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 2","key":"1243_CR48","first-page":"734","volume":"78","author":"K Queeney","year":"2019","unstructured":"Queeney K, Housley W, Sokolov J, Long A. Fri0131 Elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib. Ann Rheum Dis. 2019;78(Suppl 2):734\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1243_CR49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198133","volume":"13","author":"SI Bekkelund","year":"2018","unstructured":"Bekkelund SI, Johnsen SH. Creatine kinase is associated with reduced inflammation in a general population: the Troms\u00f8 study. PLoS ONE. 2018;13(5): e0198133.","journal-title":"PLoS ONE"},{"issue":"7182","key":"1243_CR50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","volume":"318","author":"SH Woolf","year":"1999","unstructured":"Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318(7182):527\u201330.","journal-title":"BMJ"},{"issue":"2","key":"1243_CR51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1243_CR52","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1243_CR53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.21630","volume":"187","author":"T Bieber","year":"2022","unstructured":"Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br J Dermatol. 2022;187(3):338\u201352.","journal-title":"Br J Dermatol"},{"issue":"10246","key":"1243_CR54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"1243_CR55","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1243_CR56","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1243_CR57","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10348","key":"1243_CR58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"1","key":"1243_CR59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1243_CR60","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2056\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10290","key":"1243_CR61","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"10290","key":"1243_CR62","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381.","journal-title":"Lancet"},{"issue":"9","key":"1243_CR63","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1243_CR64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis. JAMA Dermatol. 2022;158(4):404\u201313.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01243-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:45:07Z","timestamp":1726145107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01243-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1243"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01243-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors disclose the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Mark G. Kirchhof has been an advisor, consultant and\/or speaker for: AbbVie, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, Recordati, Sun Pharma, Therakos, and UCB. Vimal H. Prajapati has been an advisor, consultant, and\/or speaker for: AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Cipher, Eczema Society of Canada, Eli Lilly, Galderma, GSK, Homeocan, Janssen, LEO Pharma, L\u2019Or\u00e9al, Medexus, Novartis, Organon, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, and UCB; investigator for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Takeda, and UCB; and received grants from: AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Melinda Gooderham has been a speaker, investigator, consultant or advisory board member for: AbbVie, Acelyrin, Amgen, Akros, AnaptysBio, Apogee, Arcutis, Aristea, Aslan, Bausch Health, Boehringer Ingelheim, BMS, Coherus, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, Janssen, Kyowa Kirin, LEO Pharma, Medimmune, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Union and Ventyx. Chih-ho Hong has been an investigator and\/or consultant and\/or speaker for: AbbVie, Amgen, Arcutis, Bausch Health, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Galderma, GSK, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Roche, and UCB. Charles W. Lynde has been a speaker, consultant, or principal investigator for: AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Fresnius Kabi, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Oreal, Medexus, MedX, Merck, MoonLake, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, Sun Pharma, TEVA, Tribute, UCB, Valeant, Viatris, and Volo Health. Catherine Maari has been an advisor, an investigator, a consultant and\/or speaker for: AbbVie, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, Tarsus, Ventyx and UCB. Irina Turchin has been a speaker, consultant, or principal investigator for AbbVie, Amgen, Arcutis, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Mallinckrodt, Moonlake, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB. Kim A. Papp has been a speaker, investigator, consultant, advisory board member, and\/or scientific officer for: AbbVie, Acelyrin, Akros, Amgen, Anacor, Aralez Pharmaceuticals, Arcutis, Avillion, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Celltrion, Coherus, CorEvitas, Dermavant, Dermira, Dice Pharmaceuticals, Dow Pharma, Eli Lilly, Evelo, Forbion, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Merck (MSD), Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}